Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             592 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A comparison of the effects on cognitive function of E-5842 administered as a single or multiple dose Taubel, J.
 2000
 10 S3 p. 292-
1 p.
 artikel
2 Acute and chronic treatment with the selective glucocorticoid receptor antagonists ORG 34850, ORG 34116 and ORG 34517 alters multiple parameters of the rat hypothalamic-pituitary-adrenocortical system Bachmann, C.G.
 2000
 10 S3 p. 271-
1 p.
 artikel
3 Acute and subchronic effects of MDMA (“ecstasy”) on anxiety in the “elevated plus maze test” in male mice Maldonado, E.
 2000
 10 S3 p. 341-342
2 p.
 artikel
4 Acute pharmacotherapy of depression in old age: A systematic analysis focussing on numbers needed to treat Katona, C.
 2000
 10 S3 p. 145-146
2 p.
 artikel
5 A double-blind, randomized, placebo controlled study of the effects on wake EEG of 2 doses of naftidrofuryl using a cross-over design in elderly healthy male volunteers Boeijinga, P.H.
 2000
 10 S3 p. 363-
1 p.
 artikel
6 A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients Wright, P.
 2000
 10 S3 p. 304-
1 p.
 artikel
7 Adrenomedullin and the regulation of HPA-axis by ANP and CNP Jahn, H.
 2000
 10 S3 p. 395-396
2 p.
 artikel
8 Adverse effects of the comedication of neuroleptics and antidepressants Grohmann, R.
 2000
 10 S3 p. 112-113
2 p.
 artikel
9 A genetic polymorphism coding for 129Val in the prion protein is associated with decreased cortical gray matter volume in schizophrenic patients but not in controls Rujescu, D.
 2000
 10 S3 p. 318-319
2 p.
 artikel
10 Age-related factor structure of schizophrenic symptomatology Loza, B.
 2000
 10 S3 p. 287-
1 p.
 artikel
11 A Ginkgo biloba/Panax ginseng combination enhances memory in healthy middle aged volunteers Wesnes, K.A.
 2000
 10 S3 p. 392-
1 p.
 artikel
12 Alfa2 and beta adrenoceptors in the human brain: activation of the adenylyl cyclase system Palego, L.
 2000
 10 S3 p. 403-404
2 p.
 artikel
13 Allosteric modulation of adenosine receptors Ijzerman, A.P.
 2000
 10 S3 p. 214-215
2 p.
 artikel
14 Allosteric properties of G protein-coupled receptors — The example of muscarinic acetylcholine receptors Birdsall, N.J.M.
 2000
 10 S3 p. 213-214
2 p.
 artikel
15 Alpha-2-macroglobulin polymorphism and Alzheimer's dementia Juhász, A.
 2000
 10 S3 p. 361-362
2 p.
 artikel
16 A meta-analysis of efficacy and safety of risperidone and olanzapine Peuskens, J.
 2000
 10 S3 p. 317-
1 p.
 artikel
17 Amisulpride does not inhibit cytochrome P450 isozymes Gillet, G.
 2000
 10 S3 p. 331-332
2 p.
 artikel
18 Amisulpride: kinetics in patients with renal failure Canal, M.
 2000
 10 S3 p. 330-
1 p.
 artikel
19 Amisulpride pharmacokinetics: No difference between young and elderly subjects Canal, M.
 2000
 10 S3 p. 331-
1 p.
 artikel
20 A more favorable clinical outcome with sulpiride augmentation in a patient with chronic schizophrenia partially responsive to Olanzapine Witz, S.
 2000
 10 S3 p. 284-
1 p.
 artikel
21 A multiple-dose study of the pharmacokinetics of donepezil and sertraline in healthy volunteers Nagy, C.F.
 2000
 10 S3 p. 367-368
2 p.
 artikel
22 Amygdala or ventral hippocampal lesions at two early stages of life differentially affect prepulse inhibition of the acoustic startle response; an animal model of a neurodevelopmental disorder like schizophrenia Daenen, E.W.P.M.
 2000
 10 S3 p. 325-
1 p.
 artikel
23 A naturalistic study of changing attitudes of antipsychotic prescribing patterns in an inpatient service from Turkey Soykan, A.
 2000
 10 S3 p. 282-
1 p.
 artikel
24 A naturalistic study of reboxetine in the Spanish psychiatric practice Bobes, J.
 2000
 10 S3 p. 242-
1 p.
 artikel
25 A new model to assess stimulus processing and behavior control in humans following experimental induction of emotions Lemke, M.R.
 2000
 10 S3 p. 399-
1 p.
 artikel
26 Angiotensin-converting-enzyme gene I/D polymorphism is associated with hyperactivity of the HPA system in depressive patients Minov, C.
 2000
 10 S3 p. 233-
1 p.
 artikel
27 Anhedonia and negative symptomatology in acute schizophrenic inpatients Kollias, C.T.
 2000
 10 S3 p. 398-
1 p.
 artikel
28 Animal models of anxiety and depression: from behavior to genomics Hen, R.
 2000
 10 S3 p. 107-
1 p.
 artikel
29 Animal models of autism Gerrits, M.A.F.M.
 2000
 10 S3 p. 148-149
2 p.
 artikel
30 An international survey on information needs of patients with schizophrenia and their carers and management issues most frequently encountered by professional care team members Wærner, T.
 2000
 10 S3 p. 297-
1 p.
 artikel
31 Anixiolytic effects of alprasolam in elderly patients Filovska, V.
 2000
 10 S3 p. 409-
1 p.
 artikel
32 An open study of buspirone augmentation of neuroleptics in schizophrenic patients Sirota, P.
 2000
 10 S3 p. 283-
1 p.
 artikel
33 An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone Daniel, D.G.
 2000
 10 S3 p. 289-
1 p.
 artikel
34 Antidepressant associated suicidality Healy, D.
 2000
 10 S3 p. 260-
1 p.
 artikel
35 Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients Schatzberg, A.F.
 2000
 10 S3 p. 225-226
2 p.
 artikel
36 Antidepressant or immunomodulator induced regulation of cell signalling in brain and immune system Kovár̆ů, H.
 2000
 10 S3 p. 269-270
2 p.
 artikel
37 Antidopaminergic effects of acute tyrosine depletion in healthy subjects and patients with mania McTavish, S.F.B.
 2000
 10 S3 p. 138-139
2 p.
 artikel
38 Antipsychotic-induced parkinsonism in newly treated outpatients Schillevoort, I.
 2000
 10 S3 p. 314-
1 p.
 artikel
39 Anxiolysis associated with antidepressant response to bupropion sustained release or sertraline Rush, A.J.
 2000
 10 S3 p. 236-
1 p.
 artikel
40 Anxiolytic like activity of cyamemazine in mice models of anxiety Bourin, M.
 2000
 10 S3 p. 335-
1 p.
 artikel
41 A one-year continuation study of lamotrigine treatment in bipolar depression Huffman, R.
 2000
 10 S3 p. 237-
1 p.
 artikel
42 A one year cost-effectiveness model for the treatment of chronic schizophrenia in Belgium De Hert, M.
 2000
 10 S3 p. 316-
1 p.
 artikel
43 A one-year open-label study of the safety and efficacy of lamotrigine in the treatment of bipolar depression Bentley, B.
 2000
 10 S3 p. 236-237
2 p.
 artikel
44 A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response Feltner, D.E.
 2000
 10 S3 p. 344-345
2 p.
 artikel
45 A placebo-controlled study of sertraline in generalized social phobia Van Ameringen, M.A.
 2000
 10 S3 p. 335-
1 p.
 artikel
46 A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzheimer's disease Panisset, M.
 2000
 10 S3 p. 355-
1 p.
 artikel
47 Are suicide attempts associated with polymorphisms in serotonergic genes? Rujescu, D.
 2000
 10 S3 p. 401-
1 p.
 artikel
48 A reversible animal models of neuromotor diskinesias, proposed by intrastriatal multiple drugs microinjection Tkachenko, B.I.
 2000
 10 S3 p. 385-
1 p.
 artikel
49 Asperger's disorder in the emergency psychiatric setting Raja, M.
 2000
 10 S3 p. 385-386
2 p.
 artikel
50 Assessing the validity of a model of cost-effectiveness of fluvoxamine in depression in France using observational data on treatment patterns Piercy, J.
 2000
 10 S3 p. 238-
1 p.
 artikel
51 Association of angiotensin I converting enzyme gene I/D polymorphism with therapeutic outcome in depressive disorder Baghai, T.C.
 2000
 10 S3 p. 232-
1 p.
 artikel
52 Association study of affective disorders with genetic polymorphisms of monoamine oxidases Müller-Siecheneder, F.
 2000
 10 S3 p. 259-
1 p.
 artikel
53 Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3 Rujescu, D.
 2000
 10 S3 p. 259-260
2 p.
 artikel
54 Atypical antipsychotics and dopamine D1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat Ahlenius, S.
 2000
 10 S3 p. 308-
1 p.
 artikel
55 Atypical neuroleptics and autism Van Engeland, H.
 2000
 10 S3 p. 151-152
2 p.
 artikel
56 Auditory evoked potentials as indicator of serotonergic neuronal activity — An animal study using microinjection techniques into the dorsal raphe nucleus Juckel, G.
 2000
 10 S3 p. 275-
1 p.
 artikel
57 Author Index 2000
 10 S3 p. 411-420
10 p.
 artikel
58 Autonomic neurocardiac effects of benzodiazepines: A comparison between midazolam, diazepam and lorazepam Agelink, M.W.
 2000
 10 S3 p. 343-
1 p.
 artikel
59 Autonomic neurocardiac regulation in major depressive disorder Volkers, A.C.
 2000
 10 S3 p. 235-236
2 p.
 artikel
60 A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania Keck Jr., P.E.
 2000
 10 S3 p. 297-
1 p.
 artikel
61 Baseline characteristics of major depressive disorder patients in clinical trials: Is there a transatlantic difference? Niklson, I.A.
 2000
 10 S3 p. 234-
1 p.
 artikel
62 Behavioral and biochemical studies on the central effects of midazolam and allopregnanolone Członkowska, A.
 2000
 10 S3 p. 366-
1 p.
 artikel
63 Behavioral effects of cannabinoid agonists Lichtman, A.H.
 2000
 10 S3 p. 183-184
2 p.
 artikel
64 Behavioural asymmetry as a predictor of acute treatment efficacy in paranoid schizophrenia Loza, B.
 2000
 10 S3 p. 286-287
2 p.
 artikel
65 Behavioural challenges and functional brain imaging in anxiety disorders Malizia, A.L.
 2000
 10 S3 p. 196-197
2 p.
 artikel
66 Benefits and risks of antidepressants in hospital use Reyntens, J.
 2000
 10 S3 p. 244-
1 p.
 artikel
67 Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine, or risperidone Simpson, G.M.
 2000
 10 S3 p. 289-
1 p.
 artikel
68 Benzodiazepines effects evaluation based on experimental pharmacogenetic data in humans Nadorov, S.A.
 2000
 10 S3 p. 354-355
2 p.
 artikel
69 Better than well on antidepressants Healy, H.
 2000
 10 S3 p. 261-
1 p.
 artikel
70 Beyond phrenology: using functional MRI to study brain dynamics Berns, G.S.
 2000
 10 S3 p. 180-
1 p.
 artikel
71 Bidirectional pharmacological treatment (selegiline and donepezil) in cognitive impairment of Alzheimer Disease — A possibility Gheorghe, M.D.
 2000
 10 S3 p. 356-357
2 p.
 artikel
72 Bipolar disorder: A cyclical condition requiring a multiphasic approach to management Kusumakar, V.
 2000
 10 S3 p. 240-241
2 p.
 artikel
73 Bipolar II chronic depression: effects of age at onset on clinical features Benazzi, F.
 2000
 10 S3 p. 219-
1 p.
 artikel
74 Body dysmorphic disorder: assessment and treatment with serotonergic drugs Hollander, E.
 2000
 10 S3 p. 125-126
2 p.
 artikel
75 Brain activation in schizophrenic patients and healthy controls during working memory and mental arithmetic. a functional magnetic resonance imaging (fMRI) study Lund, A.
 2000
 10 S3 p. 291-
1 p.
 artikel
76 Brain circuits involved in craving Nutt, D.J.
 2000
 10 S3 p. 135-136
2 p.
 artikel
77 Burden of depression over life is related to increased central catecholamine turnover in patients with treatment-refractory depressive illness Ehnvall, A.
 2000
 10 S3 p. 388-
1 p.
 artikel
78 cAMP signalling system in the pharmacotherapy and pathophysiology of bipolar disorder Perez, J.
 2000
 10 S3 p. 143-
1 p.
 artikel
79 Can quality management improve the treatment of schizophrenic outpatients? Seemann, U.
 2000
 10 S3 p. 332-333
2 p.
 artikel
80 Can we model GAD experimentally in volunteers? Szabadi, E.
 2000
 10 S3 p. 174-
1 p.
 artikel
81 Cardiologic relations of citalopram drop infusion therapy Kovács, G.
 2000
 10 S3 p. 255-
1 p.
 artikel
82 Cardiovascular risk factors and lithium in bipolar disorder Klumpers, U.M.H.
 2000
 10 S3 p. 235-
1 p.
 artikel
83 CB1 receptor mediated effects on brain neurotransmitter systems Van Vliet, B.J.
 2000
 10 S3 p. 182-183
2 p.
 artikel
84 CCK and panic disorder Bradwejn, J.
 2000
 10 S3 p. 124-125
2 p.
 artikel
85 Cerebrolysin in the treatment of dementia: open-label study with a neurotrophic agent Rainer, M.
 2000
 10 S3 p. 355-356
2 p.
 artikel
86 Cerebrospinal fluid tau phosphorylated at threonine 231 compared to total tau in Alzheimer's disease patients, controls, and subjects at risk Bürger, K.
 2000
 10 S3 p. 371-
1 p.
 artikel
87 Change over time in psychological distress of inpatients with severe mental disorders Ritsner, M.
 2000
 10 S3 p. 397-
1 p.
 artikel
88 Changes of ANP plasma concentrations in alcoholics during withdawal Kiefer, F.
 2000
 10 S3 p. 378-
1 p.
 artikel
89 Choice of method and lethality in suicidal behaviour — overdoses during a 14 years period in Baranya region, Hungary Fekete, S.
 2000
 10 S3 p. 267-
1 p.
 artikel
90 Cholecystokinin-antisense oligodeoxynucleotides: a new strategy in the approach to anxiety? Cohen, H.
 2000
 10 S3 p. 337-
1 p.
 artikel
91 Cholinesterase inhibitors in the treatment of dementia Anand, R.
 2000
 10 S3 p. 192-193
2 p.
 artikel
92 Chronobiological lithium effects in rats with lesion of suprachiasmatic nucleus Zamoshchina, T.
 2000
 10 S3 p. 268-
1 p.
 artikel
93 Citalopram versus amitriptyline in elderly patients with or without dementia. A Danish multicentre trial in general practice Rosenberg, C.
 2000
 10 S3 p. 278-
1 p.
 artikel
94 Clinical, biological and treatment characteristics of intermittent explosive disorder Coccaro, E.F.
 2000
 10 S3 p. 208-209
2 p.
 artikel
95 Clinical characteristics in psychogeriatric patients with orthostatic hypotension and low blood pressure Zacharof, A.K.
 2000
 10 S3 p. 357-
1 p.
 artikel
96 Clinical consequences of the control of NA and 5-HT release in antidepressant therapy Blier, P.
 2000
 10 S3 p. 161-
1 p.
 artikel
97 Clinical predictors of acute response with quetiapine in psychotic mood disorders Zarate, C.A.
 2000
 10 S3 p. 300-
1 p.
 artikel
98 Clozapine is efficient in long-term treatment of negative syndrome, but no cognitive functioning, in schizophrenia? A three-year follow-up study Marinković, D.
 2000
 10 S3 p. 321-
1 p.
 artikel
99 Clozapine plasma levels and time to clinical response in a standardized trial La Pia, S.
 2000
 10 S3 p. 307-308
2 p.
 artikel
100 Clozapine treatment of different psychoses Gaszner, P.
 2000
 10 S3 p. 285-
1 p.
 artikel
101 Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression Hawley, C.J.
 2000
 10 S3 p. 231-
1 p.
 artikel
102 Cognition, antipsychotic drugs, and treatment response Meltzer, H.
 2000
 10 S3 p. 180-181
2 p.
 artikel
103 Cognitive and sleep effects of antihistamines: Human studies Alford, C.
 2000
 10 S3 p. 202-203
2 p.
 artikel
104 Cognitive components of somatosensory evoked potentials in major depressive disorder Dietl, T.
 2000
 10 S3 p. 273-
1 p.
 artikel
105 Cognitive symptoms in schizophrenic patients treated with risperidone compared to other neuroleptics Klauder, A.
 2000
 10 S3 p. 296-297
2 p.
 artikel
106 Colostrinin — a polypeptide isolated from early milk, for treatment of Alzheimer's disease Leszek, J.
 2000
 10 S3 p. 364-
1 p.
 artikel
107 Combination treatment for chronic hepatitis C with interferon-alpha and ribavirin in psychiatric patients and drug addicts compared to controls Schäfer, M.
 2000
 10 S3 p. 377-378
2 p.
 artikel
108 Combined striatal dopamin transporter and dopamin D2-receptor-SPECT in drug-naiv schizophrenic patients: a 99mTc-TRODAT-1-123I-IBZM-SPECT study Meisenzahl, E.M.
 2000
 10 S3 p. 324-325
2 p.
 artikel
109 Comedication in bipolar disorders: a pharmacological view Ackenheil, M.
 2000
 10 S3 p. 156-157
2 p.
 artikel
110 Comparison of antidepressant-like activity of Lu 28-179, a selective σ2 ligand, citalopram and imipramine in a chronic mild stress model of depression in rats Papp, M.
 2000
 10 S3 p. 266-267
2 p.
 artikel
111 Comparison of indications and treatment outcomes of risperidone in elderly and younger patients Van Zonneveld, Th.H.
 2000
 10 S3 p. 293-
1 p.
 artikel
112 Comparison of psychomotor and memory impairment with zaleplon versus other hypnotics: an integrated analysis Darwish, M.
 2000
 10 S3 p. 394-395
2 p.
 artikel
113 Comparison of the costs and effects of treatment with risperidone versus olanzapine in daily practice Loos, J.C.M.
 2000
 10 S3 p. 292-293
2 p.
 artikel
114 Comparison of the effects of the monoamines oxidase inhibitor tranylcypromine and its 4-fluoro analogue in the forced swimming test in mice Bourin, M.
 2000
 10 S3 p. 223-
1 p.
 artikel
115 Comparison of the residual effects of zaleplon and zolpidem after administration during the night Hindmarch, I.
 2000
 10 S3 p. 394-
1 p.
 artikel
116 Compliance with neuroleptics in schizophrenic patients prior to inpatient treatment Rittmannsberger, H.
 2000
 10 S3 p. 299-
1 p.
 artikel
117 Comprehensive treatment of social anxiety disorder Baldwin, D.
 2000
 10 S3 p. 187-189
3 p.
 artikel
118 Contrasting effects of typical and atypical antipsychotics on neuronal viability and functioning of the anterior cingulate region in chronic schizophrenia: A MRSI study Braus, D.F.
 2000
 10 S3 p. 285-286
2 p.
 artikel
119 Co-occurrence of OCD and HD in a nuclear family De Marchi, N.
 2000
 10 S3 p. 356-
1 p.
 artikel
120 Coordinate manifestation in corticotropin-releasing hormone (CRH) and monoaminergic systems after chronic variable stress in the rat brain Nagashima, H.
 2000
 10 S3 p. 234-
1 p.
 artikel
121 Coping-orientated treatment and atypical neuroleptics in an integrated treatment approach for patients with schizophrenia Schaub, A.
 2000
 10 S3 p. 327-
1 p.
 artikel
122 Coprescription of antipsychotics and antidepressants: Why, when and how? Fleischhacker, W.W.
 2000
 10 S3 p. 111-112
2 p.
 artikel
123 Correlation between alpha2-adrenoreceptors and symptom severity in major depression Marazziti, D.
 2000
 10 S3 p. 256-
1 p.
 artikel
124 Cortical surface and regional variability in patients with schizophrenia and healthy controls Meisenzahl, E.M.
 2000
 10 S3 p. 323-
1 p.
 artikel
125 Cortisol promotes non-REM sleep in patients with major depression Schmid, D.A.
 2000
 10 S3 p. 256-
1 p.
 artikel
126 Cortisol response to the Dex/CRH test predicts medium-term-outcome in patients with remitted depression Zobel, A.W.
 2000
 10 S3 p. 275-276
2 p.
 artikel
127 Costs-benefits of resource utilization in the Quebec welfare recipients population using two atypical drug products Castilloux, A.-M.
 2000
 10 S3 p. 328-
1 p.
 artikel
128 CRH, HPA system hyperactivity and depression Zobel, A.W.
 2000
 10 S3 p. 275-
1 p.
 artikel
129 CYP2D6 phenotype and genotype analysis in polymedicated depressed inpatients Haffen, E.
 2000
 10 S3 p. 238-239
2 p.
 artikel
130 Decreased GSK-3̵ immunoreactivity in postmortem frotal cortex of schizophrenic patients Kozlovsky, N.
 2000
 10 S3 p. 333-
1 p.
 artikel
131 Decreasing the risk of tardive dyskinesia Chirita, R.
 2000
 10 S3 p. 361-
1 p.
 artikel
132 Deficit/nondeficit schizophrenia: psychopathological evaluations and treatment Leuci, E.
 2000
 10 S3 p. 310-
1 p.
 artikel
133 Depression, disability and service use in primary health care in six countries Herrman, H.
 2000
 10 S3 p. 228-
1 p.
 artikel
134 Depression during mania: treatment response to olanzapine or placebo Baker, R.W.
 2000
 10 S3 p. 246-247
2 p.
 artikel
135 Depression in general practice: Symptoms recognised and treated Rasmussen, J.G.C.
 2000
 10 S3 p. 233-
1 p.
 artikel
136 Depression in the psychiatric practice in Switzerland: a survey study Holsboer-Trachsler, E.
 2000
 10 S3 p. 262-263
2 p.
 artikel
137 Depression measures and motor side-effects among schizophrenic inpatients Kontaxakis, V.P.
 2000
 10 S3 p. 313-
1 p.
 artikel
138 Depression, smoking, and cortisol response to stress Netter, P.
 2000
 10 S3 p. 376-
1 p.
 artikel
139 Diabetic neuropathic pain management with venlafaxine extended release Kunz, N.R.
 2000
 10 S3 p. 389-
1 p.
 artikel
140 Diagnostic dilemmas in social anxiety disorder and posttraumatic stress Stein, D.J.
 2000
 10 S3 p. 186-187
2 p.
 artikel
141 Differential actions of the new antipsychotic agents Moore, N.A.
 2000
 10 S3 p. 321-322
2 p.
 artikel
142 Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms and the pro-/anti-inflammatory cytokine balance Kelly, J.P.
 2000
 10 S3 p. 278-279
2 p.
 artikel
143 Differential effects of tricyclic antidepressants and paroxetine on gait performance in depression Lemke, M.R.
 2000
 10 S3 p. 254-
1 p.
 artikel
144 Differential efficacy of venlafaxine ER and fluoxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder Silverstone, P.H.
 2000
 10 S3 p. 230-231
2 p.
 artikel
145 Differentiation between autism and multiple complex developmentadisorder in the response to psychosocial stress Jansen, L.M.C.
 2000
 10 S3 p. 392-393
2 p.
 artikel
146 Dimensions of psychopathology in schizophrenia: a factor analysis of the amisulpride database Rein, W.
 2000
 10 S3 p. 315-
1 p.
 artikel
147 Dimensions vs categories in OCD-related disorders Marazziti, D.
 2000
 10 S3 p. 207-208
2 p.
 artikel
148 Discriminative stimulus properties of the selective serotonin uptake inhibitor, citalopram, in rats: Generalization with duloxetine, venlafaxine and clomipramine, but blockade by mirtazapine and mianserin Dekeyne, A.
 2000
 10 S3 p. 217-218
2 p.
 artikel
149 Disruption of feeding behaviour in corticotropin releasing hormone type-1 receptor (CRHR1) deficient mice is dependent on glucocorticoids Preil, J.
 2000
 10 S3 p. 405-
1 p.
 artikel
150 Distinct differences in neurochemical effects produced by various 1,2,3,4-tetrahydroisoquinolines on dopaminergic structures of rat brain Antkiewicz-Michaluk, L.
 2000
 10 S3 p. 365-
1 p.
 artikel
151 Diurnal variation of cortisol in panic disorder Bandelow, B.
 2000
 10 S3 p. 346-347
2 p.
 artikel
152 Do animal models of stroke predict clinical utility? Vornov, J.J.
 2000
 10 S3 p. 152-153
2 p.
 artikel
153 Don epezil for Al zheimer's D isease — The donald study — a multicenter 24 weeks clinical trial in Germany Froelich, L.
 2000
 10 S3 p. 360-361
2 p.
 artikel
154 Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease Engedal, K.
 2000
 10 S3 p. 368-
1 p.
 artikel
155 Donepezil in therapy-refractory depression Kemmerich, M.
 2000
 10 S3 p. 264-
1 p.
 artikel
156 Donepezil provides relevant therapeutic benefits in different domains to “real world” patients with Alzheimer's disease Berger, F.
 2000
 10 S3 p. 369-
1 p.
 artikel
157 Dopamine and serotonin plasma blood level in adolescents with schizophrenia during perphenazine therapy Rajewski, A.
 2000
 10 S3 p. 322-
1 p.
 artikel
158 Dose-dependent antidepressive effect of new analogues of excitatory amino acids in forced swimming test Parshev, V.V.
 2000
 10 S3 p. 280-281
2 p.
 artikel
159 Dose-dependent enhancement of cognitive performance in young volunteers by a single doses of Ginseng Kennedy, D.
 2000
 10 S3 p. 391-392
2 p.
 artikel
160 Dose-dependent enhancement of cognitive performance in young volunteers following single doses of Ginkgo biloba Kennedy, D.
 2000
 10 S3 p. 391-
1 p.
 artikel
161 Do the benzodiazepines still have a role in the treatment of GAD? Lader, M.
 2000
 10 S3 p. 173-
1 p.
 artikel
162 Double-blind trial of paroxetine for specific phobia Benjamin, J.
 2000
 10 S3 p. 353-
1 p.
 artikel
163 Doxepin in the treatment of primary insomnia — A placebo-controlled, double-blind, polysomnographic study Hajak, G.
 2000
 10 S3 p. 248-249
2 p.
 artikel
164 Drug attitude inventory, spanish-adapted version García Cabeza, I.
 2000
 10 S3 p. 298-299
2 p.
 artikel
165 Drug combination treatment in acute and subacute states of schizophrenia and schizoaffective disorder Müller, M.J.
 2000
 10 S3 p. 327-328
2 p.
 artikel
166 Drug daily dosage in schizophrenia inpatients receiving conventional versus atypical neuroleptic agents Ritsner, M.
 2000
 10 S3 p. 299-300
2 p.
 artikel
167 DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potential Van Vliet, B.J.
 2000
 10 S3 p. 293-
1 p.
 artikel
168 DU 127090: A highly potent, atypical dopamine receptor ligand — Behavioral effects of DU 127090 in Cebus non-human primates Casey, D.E.
 2000
 10 S3 p. 333-
1 p.
 artikel
169 DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro Van Vliet, B.J.
 2000
 10 S3 p. 294-
1 p.
 artikel
170 DU 127090: a highly potent, atypical dopamine receptor ligand — partial agonist character in neurochemistry assays in vivo Long, S.K.
 2000
 10 S3 p. 295-
1 p.
 artikel
171 DU 127090: a highly potent, atypical dopamine receptor ligand — pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomography De Vries, M.H.
 2000
 10 S3 p. 294-
1 p.
 artikel
172 Economic aspects of nefazodone, CBASP, and their combination for the treatment of chronic depression Russell, J.M.
 2000
 10 S3 p. 239-
1 p.
 artikel
173 EEG spatial organization of stress-reactions at different emotionality levels Sviderskaya, N.E.
 2000
 10 S3 p. 407-408
2 p.
 artikel
174 Effectiveness of tramadol as antidepressant in the learned-helplessness model of depression Micó, J.A.
 2000
 10 S3 p. 251-252
2 p.
 artikel
175 Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine Kinon, B.J.
 2000
 10 S3 p. 305-306
2 p.
 artikel
176 Effect of acetaldehyde on brain catalase activity in the rat Bardina, L.
 2000
 10 S3 p. 409-
1 p.
 artikel
177 Effect of amitriptyline treatment on the mRNA levels of the transcription factors c-jun, c-fos and zif 268 on immortalized lymphocytes of depressed patients Zill, P.
 2000
 10 S3 p. 253-254
2 p.
 artikel
178 Effect of long-term olanzapine treatment on weight change in schizophrenia Gilmore, J.
 2000
 10 S3 p. 305-
1 p.
 artikel
179 Effects of active immunization by serotonin-protein conjugate on passive avoidance and brain monoamine containing in two inbred mice strains Basharova, L.A.
 2000
 10 S3 p. 391-
1 p.
 artikel
180 Effects of an atypical neuroleptic EMD 128 130 on sleep EEG and nocturnal hormone secretion in young normal controls Held, K.
 2000
 10 S3 p. 329-330
2 p.
 artikel
181 Effects of cholinergic enhancement on working memory (WM) performance and prefrontal cortex (PFC) activity in young and older healthy subjects Pietrini, P.
 2000
 10 S3 p. 402-
1 p.
 artikel
182 Effects of cocaine on sexual activity of exhausted male rats Belozertseva, I.
 2000
 10 S3 p. 409-410
2 p.
 artikel
183 Effects of dexamethasone on various immunological parameters in patients with major depression Schuld, A.
 2000
 10 S3 p. 272-
1 p.
 artikel
184 Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease Gauthier, S.
 2000
 10 S3 p. 359-360
2 p.
 artikel
185 Effects of long-term voluntary ethanol intake on the relative expression of NMDA receptor subunits and splice variants in the rat brain Räder, H.
 2000
 10 S3 p. 380-
1 p.
 artikel
186 Effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) on anxiety in the “social interaction test” in male mice Maldonado, E.
 2000
 10 S3 p. 341-
1 p.
 artikel
187 Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression Debonnel, G.
 2000
 10 S3 p. 252-
1 p.
 artikel
188 Effects of new antipsychotics on serum prolactin and testosterone in schizophrenic patients Han, D.H.
 2000
 10 S3 p. 291-
1 p.
 artikel
189 Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients Gönül, A.S.
 2000
 10 S3 p. 283-
1 p.
 artikel
190 Effects of pharmacotherapy to depression in the period of adolescence Munjiza, M.
 2000
 10 S3 p. 261-
1 p.
 artikel
191 Effects of psychoactive compounds on network level physiology as measured with a multielectrode array Colgin, L.
 2000
 10 S3 p. 398-
1 p.
 artikel
192 Effects of psychotropic agents on plasma levels of soluble interleukin-2 and interleukin-6 receptors in bipolar mania Lee, H.C.
 2000
 10 S3 p. 227-228
2 p.
 artikel
193 Effects of reboxetine and paroxetine compared to placebo on cognitive processes in healthy volunteers Straube, E.R.
 2000
 10 S3 p. 257-
1 p.
 artikel
194 Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β1-adrenergic receptors in an animal model of depression Kelly, J.P.
 2000
 10 S3 p. 279-
1 p.
 artikel
195 Effects of reboxetine on HAM-D factors among depressed patients Ferguson, J.
 2000
 10 S3 p. 226-
1 p.
 artikel
196 Effects of risperidone and typical antipsychotics on basal ganglia volumes in patients with schizophrenia Honer, W.G.
 2000
 10 S3 p. 306-
1 p.
 artikel
197 Effects of selective 5-HT2C receptor antagonist, SB 242084, on anxiety and depressive-like behaviour in mice Sukhotina, I.A.
 2000
 10 S3 p. 344-
1 p.
 artikel
198 Effects of the 5-HT2C agonist, RO 60-0175, on the antidepressant drug action in the mouse forced swimming test Bourin, M.
 2000
 10 S3 p. 223-
1 p.
 artikel
199 Effects of the long lasting somatostatin analogue octreotide on sleep EEG in young men Ziegenbein, M.
 2000
 10 S3 p. 407-
1 p.
 artikel
200 Effects of tiapride on anxiety tested in the light-dark box in male mice Cárdenas, J.
 2000
 10 S3 p. 340-341
2 p.
 artikel
201 Effects of tryptophan depletion and repetitive transcranial magnetic stimulation on human sleep Hajak, G.
 2000
 10 S3 p. 247-248
2 p.
 artikel
202 Efficacy and safety of donepezil in patients with Alzheimer's disease: preliminary findings from the Australian subset of a global clinical experience study Brodaty, H.
 2000
 10 S3 p. 367-
1 p.
 artikel
203 Efficacy and safety of glycine site agonists of the N-methyl-D-aspartate receptor in schizophrenia treatment Heresco-Levy, U.
 2000
 10 S3 p. 212-
1 p.
 artikel
204 Efficacy and tolerability of mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholia Guelfi, J.D.
 2000
 10 S3 p. 266-
1 p.
 artikel
205 Efficacy and tolerability of risperidone as combination therapy in bipolar mania: results from a randomised, double-blind study (RIS-INT-46) Yatham, L.N.
 2000
 10 S3 p. 250-251
2 p.
 artikel
206 Efficacy and tolerability of risperidone versus placebo in combination with lithium or valproate in acute mania Sachs, G.
 2000
 10 S3 p. 240-
1 p.
 artikel
207 Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo Carson, W.H.
 2000
 10 S3 p. 309-310
2 p.
 artikel
208 Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder De Veaugh-Geiss, J.
 2000
 10 S3 p. 393-
1 p.
 artikel
209 Efficacy of quetiapine compared with haloperidol and placebo in the short-term treatment of acute schizophrenia Schulz, S.C.
 2000
 10 S3 p. 302-303
2 p.
 artikel
210 Efficacy of reboxetine in patients with severe major depression Montgomery, S.
 2000
 10 S3 p. 226-
1 p.
 artikel
211 Efficacy of risperidone treatment for psychoses associated with paraphrenia, vasular, senile or Parkinson's dementia in 10 geriatric patients: A case series Krsteska, R.
 2000
 10 S3 p. 373-374
2 p.
 artikel
212 Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder Conley, R.R.
 2000
 10 S3 p. 342-343
2 p.
 artikel
213 Efficacy of short and long-term venlafaxine ER treatment on somatic and psychic symptoms of GAD Hackett, D.
 2000
 10 S3 p. 337-
1 p.
 artikel
214 Efficacy of venlafaxine ER in social adjustment in patients with generalized anxiety disorder Boyer, P.
 2000
 10 S3 p. 336-
1 p.
 artikel
215 Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment De Clercq, M.
 2000
 10 S3 p. 241-
1 p.
 artikel
216 Efficacy of venlafaxine in depressed patients after switching from prior SSRI treatment Reynaert, C.
 2000
 10 S3 p. 241-
1 p.
 artikel
217 Effortful and effortless deficits of cognitive processing in clinical depression Politis, A.
 2000
 10 S3 p. 229-
1 p.
 artikel
218 Electroconvulsive therapy in treatment resistant bipolar disorder — Case reports Soares, M.B.M.
 2000
 10 S3 p. 258-
1 p.
 artikel
219 Endogenous low molecular weight factors support extensive CNS axon growth Benowitz, L.I.
 2000
 10 S3 p. 153-
1 p.
 artikel
220 Endotoxin-induced emotional and cognitive disturbances in healthy volunteers are associated with increased plasma levels of cytokines and cortisol Reichenberg, A.
 2000
 10 S3 p. 405-406
2 p.
 artikel
221 Ethimizol effect on the acoustical function by method audiometry (registration of acoustic evoked potentials) Petrova, N.N.
 2000
 10 S3 p. 383-384
2 p.
 artikel
222 Evaluation of incidence, prevalence and time-course of depression after acute myocardial infarction Sathananthan, K.
 2000
 10 S3 p. 220-
1 p.
 artikel
223 Evaluation of working memory in functional MR imaging with different memory tasks Meisenzahl, E.M.
 2000
 10 S3 p. 323-
1 p.
 artikel
224 Evidence for an association between a G-protein-β3-gene variant with depression and response to antidepressant treatment Zill, P.
 2000
 10 S3 p. 253-
1 p.
 artikel
225 Excess TPH 17 779C allele in surviving cotwins of monozygotic twin suicide victims Roy, A.
 2000
 10 S3 p. 217-
1 p.
 artikel
226 Experience with buprenorphine Fischer, G.
 2000
 10 S3 p. 137-138
2 p.
 artikel
227 Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low-dosages of the atypical antipsychotic Klieser, E.
 2000
 10 S3 p. 344-
1 p.
 artikel
228 Fast adaptive changes of the sleep regulatory system after the putative antidepressant EMD 68 843 Murck, H.
 2000
 10 S3 p. 277-278
2 p.
 artikel
229 Fatal neuroleptic intoxications identified at autopsy in Vienna from 1991 to 1997 Schreinzer, D.
 2000
 10 S3 p. 333-334
2 p.
 artikel
230 Fibromyalgia and the 5-HTR2c Cys23Ser mutation Spaeth, M.
 2000
 10 S3 p. 407-
1 p.
 artikel
231 Five-year maintenance treatment with citalopram in recurrent major depressive disorder Vavrušová, L.
 2000
 10 S3 p. 256-257
2 p.
 artikel
232 Flunitrazepam compared to Nitrazepam and placebo at alcoholics Lazarova, V.
 2000
 10 S3 p. 380-381
2 p.
 artikel
233 Fluoxetine and amitriptyline: differential cognitive effects in depressed patients Ivkovic, M.
 2000
 10 S3 p. 264-
1 p.
 artikel
234 Fluoxetine in panic disorder: a randomized, placebo-controlled study Michelson, D.
 2000
 10 S3 p. 220-221
2 p.
 artikel
235 fMRI in normal functioning and psychiatric disorders Gabrieli, J.D.E.
 2000
 10 S3 p. 179-180
2 p.
 artikel
236 Follow-up investigation in patients with Alzheimer's disease 24 weeks after termination of cerebrolysin therapy Ruether, E.
 2000
 10 S3 p. 357-358
2 p.
 artikel
237 Frontal and temporal enlargement of CSF spaces in agoraphobia: a morphometric CT-scan study Wurthmann, C.
 2000
 10 S3 p. 334-
1 p.
 artikel
238 Frontal lobe dysfunction and prediction to treatment outcome in obsessive-compulsive disorder Cavedini, P.
 2000
 10 S3 p. 345-
1 p.
 artikel
239 Functional MRI: current use and future prospects in human and animal research Morris, P.G.
 2000
 10 S3 p. 195-196
2 p.
 artikel
240 Functional neuroanatomy of schizophrenia McGuire, P.K.
 2000
 10 S3 p. 197-
1 p.
 artikel
241 Functional repair of global and focal ischaemic brain damage by grafts of conditionally immortal neuroepithelial stem cells Gray, J.A.
 2000
 10 S3 p. 153-154
2 p.
 artikel
242 GAD: Current treatment and costs Lecrubier, Y.
 2000
 10 S3 p. 170-171
2 p.
 artikel
243 Gammahydroxybutyrate (GHB) exhibits anxiogenic-like effects in the “elevated plus maze test” in male mice Navarro, J.F.
 2000
 10 S3 p. 340-
1 p.
 artikel
244 Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depression Martényi, F.
 2000
 10 S3 p. 221-
1 p.
 artikel
245 Gender differences in the response to sertraline versus imipramine in non-melancholic depression Baca, E.
 2000
 10 S3 p. 258-
1 p.
 artikel
246 Generalised anxiety disorder: An insight into the burden on the individual and society Wittchen, H.-U.
 2000
 10 S3 p. 350-351
2 p.
 artikel
247 Global index of safety (GIS): a new instrument to assess drug safety: application to a prospective pharmacoepidemiological study (EFESO) Sacristán, J.A.
 2000
 10 S3 p. 303-
1 p.
 artikel
248 Glucocorticoids & cognition in depression Schatzberg, A.F.
 2000
 10 S3 p. 180-
1 p.
 artikel
249 Glutamate receptors in control of dopaminergic systems Svensson, T.H.
 2000
 10 S3 p. 210-211
2 p.
 artikel
250 Haptoglobin phenotypes and genotypes in schizophrenia Maes, M.
 2000
 10 S3 p. 333-
1 p.
 artikel
251 Healthcare resource use and body mass index among individuals with schizophrenia Allison, D.B.
 2000
 10 S3 p. 290-
1 p.
 artikel
252 1H-MR-Spectroscopy of untreated depressive patients shows reduced N-acetyl aspartate, choline and myo-inositol levels in the frontal lobe Frey, R.
 2000
 10 S3 p. 280-
1 p.
 artikel
253 How to measure addictive behaviour in animal experiments Spanagel, R.
 2000
 10 S3 p. 134-135
2 p.
 artikel
254 5-HT2B/2C but not 5-HT2A receptor subtypes modulate the impulse flow dependent release of DA in the rat nucleus accumbens and striatum: Studies with morphine and amphetamine Porras, G.
 2000
 10 S3 p. 378-
1 p.
 artikel
255 5-HT-moduline, an endogenous allosteric modulator of 5-HT1B receptor Fillion, G.
 2000
 10 S3 p. 214-
1 p.
 artikel
256 Humoral component of regeneration and learning is a subcase of neurosecretion Sapronov, N.S.
 2000
 10 S3 p. 384-
1 p.
 artikel
257 Hypothalamic-pituitary-adrenal (HPA) axis activity and response to transcranial magnetic stimulation in responders and nonresponders to sleep deprivation Schüle, C.
 2000
 10 S3 p. 232-
1 p.
 artikel
258 Identification of activated protein kinase B/Akt positive neurons in the rat brain: increment of the number in the CA1 hippocampal area with aging Kubota, M.
 2000
 10 S3 p. 403-
1 p.
 artikel
259 Imidazoline receptors: potential markers for depression and targets of antidepressant drug development Halaris, A.
 2000
 10 S3 p. 224-
1 p.
 artikel
260 Impact of early intervention with intramuscular antipsychotic medication in an acute care setting Martinez, J.M.
 2000
 10 S3 p. 295-
1 p.
 artikel
261 Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder Namjoshi, M.
 2000
 10 S3 p. 247-
1 p.
 artikel
262 Implications of dichotic listening effects for dimensional structure of paranoid schizophrenia Loza, B.
 2000
 10 S3 p. 287-288
2 p.
 artikel
263 Improved avoidance learning by oxytocin administration in a high-emotional strain of Sprague-Dawley rats Hillegaart, V.
 2000
 10 S3 p. 346-
1 p.
 artikel
264 Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics Harvey, P.D.
 2000
 10 S3 p. 288-
1 p.
 artikel
265 Improvement in indices of health status following a switch to ziprasidone from conventional and novel antipsychotics Daniel, D.G.
 2000
 10 S3 p. 288-289
2 p.
 artikel
266 Improvement of CCK-4 induced panic by selective GABA-transaminase-inhibition with vigabatrin Zwanzger, P.
 2000
 10 S3 p. 339-
1 p.
 artikel
267 Improving impairment and disability in anxiety disorders with paroxetine treatment Baldwin, D.S.
 2000
 10 S3 p. 351-
1 p.
 artikel
268 Incomplete forms of the neuroleptic malignant syndrome: A continuation of a case series Žicanović, O.
 2000
 10 S3 p. 298-
1 p.
 artikel
269 Increased diagnostic accuracy in Alzheimer's disease by age-transformed hippocampal volumes Teipel, S.J.
 2000
 10 S3 p. 371-
1 p.
 artikel
270 Increased O-demethylation rate of dextromethorphan in alcohol dependent patients. A possible role of ethanol in changing cytochrome P450 2D6 activity Eisenburg, B.
 2000
 10 S3 p. 379-380
2 p.
 artikel
271 Informative morphogenetic variants in bipolar affective disorder Tényi, T.
 2000
 10 S3 p. 386-387
2 p.
 artikel
272 Inpatient treatment of schizophrenia: a real-life study of two leading atypical antipsychotics Kasper, S.
 2000
 10 S3 p. 316-317
2 p.
 artikel
273 Insights into the mechanisms of benzodiazepine dependence Doble, A.
 2000
 10 S3 p. 169-
1 p.
 artikel
274 Interaction of tricyclic antidepressants with liposomes Fis̆ar, Z.
 2000
 10 S3 p. 270-
1 p.
 artikel
275 Interrater reliability and construct validity of the SADIMoD Loonen, A.J.M.
 2000
 10 S3 p. 362-363
2 p.
 artikel
276 Intracerebroventricular antisense to inositol monophosphatase 1 reduces the enzyme activity but does not affect Li-sensitive behavior Shaltiel, G.
 2000
 10 S3 p. 221-222
2 p.
 artikel
277 Intrahippocampal infusion of an equimolar dose of endogenous μ-, δ, κ- and ORL1-receptor agonists. Effects on spatial learning in the rat Sandin, J.
 2000
 10 S3 p. 358-
1 p.
 artikel
278 In vivo effects of olanzapine and risperidone on striatal dopamine D2 receptor binding in schizophrenic patients: an 123I-IBZM SPECT study Meisenzahl, E.M.
 2000
 10 S3 p. 325-
1 p.
 artikel
279 In vivo striatal dopamine D2 receptor binding in drug-naive patients with schizophrenia compared to healthy controls: an 123I-IBZM-SPECT study Frodl, T.
 2000
 10 S3 p. 324-
1 p.
 artikel
280 Keyword index 2000
 10 S3 p. 421-424
4 p.
 artikel
281 Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia Robinson, G.
 2000
 10 S3 p. 291-292
2 p.
 artikel
282 Long term consequences in animals of a stress experience Piazza, P.V.
 2000
 10 S3 p. 163-
1 p.
 artikel
283 Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia Street, J.
 2000
 10 S3 p. 365-366
2 p.
 artikel
284 Long-term treatment with clozapine: a study with plasma levels Mauri, M.C.
 2000
 10 S3 p. 317-318
2 p.
 artikel
285 Low-dose amisulpride: some evidence for alertness-increasing properties in EEG studies Legangneux, E.
 2000
 10 S3 p. 315-
1 p.
 artikel
286 Low leptin levels, but normal BMI in patients suffering from depression or schizophrenia Kraus, T.
 2000
 10 S3 p. 405-
1 p.
 artikel
287 Low levels of antibodies to cardiolipin in first episode and chronic schizophrenia Sirota, P.
 2000
 10 S3 p. 282-283
2 p.
 artikel
288 Maladaptation to stress in schizophrenia Gispen-de Wied, C.C.
 2000
 10 S3 p. 163-164
2 p.
 artikel
289 Management of resistant depression Souery, D.
 2000
 10 S3 p. 205-206
2 p.
 artikel
290 MAO-B activity in early and late alcohol withdrawal Baştürk, M.
 2000
 10 S3 p. 375-
1 p.
 artikel
291 Marked improvement in tardive dyskinesia with olanzapine treatment: a case report Eşel, E.
 2000
 10 S3 p. 283-284
2 p.
 artikel
292 Memory assessment 25 years after ECT treatment Kohl, C.
 2000
 10 S3 p. 260-
1 p.
 artikel
293 Mentalising deficit of people with schizophrenia after recovery Herold, R.
 2000
 10 S3 p. 387-
1 p.
 artikel
294 Meta-analysis of amisulpride — A selective dopamine receptor antagonist with an “atypical” profile Leucht, S.
 2000
 10 S3 p. 326-
1 p.
 artikel
295 Methadone maintenance: the recommended dose Strain, E.C.
 2000
 10 S3 p. 136-137
2 p.
 artikel
296 Mezapam reduces basophil releasability in non-atopic allergic skin diseases Strakhova, M.
 2000
 10 S3 p. 334-
1 p.
 artikel
297 Microdialysis in parkinsonian patient basal ganglia: apomorphine effect without changes in the release of neuroactive amino acids Fedele, E.
 2000
 10 S3 p. 366-
1 p.
 artikel
298 M100907 in schizophrenic and schizoaffective patients Kablinger, A.S.
 2000
 10 S3 p. 290-
1 p.
 artikel
299 Mirtazapine and onset of action of antidepressant activity Montgomery, S.
 2000
 10 S3 p. 266-
1 p.
 artikel
300 Mirtazapine and the onset of antidepressant action: survival function analysis-response Nierenberg, A.A.
 2000
 10 S3 p. 265-
1 p.
 artikel
301 Mirtazapine has similar long-term efficacy and tolerability to citalopram and faster onset of action in the treatment of major depression Leinonen, E.
 2000
 10 S3 p. 265-
1 p.
 artikel
302 Mirtazapine in relapse prevention: a double-blind placebo-controlled study in depressed outpatients Thase, M.E.
 2000
 10 S3 p. 265-266
2 p.
 artikel
303 Mirtazapine versus amitriptyline in treatment of major depressive disorder Turan, M.
 2000
 10 S3 p. 228-229
2 p.
 artikel
304 Mismatch negativity (MMN) is modulated by dopamine D2 receptors. Combined EEG and MEG study Kähkönen, S.
 2000
 10 S3 p. 401-402
2 p.
 artikel
305 Mode of action of atypical antipsychotic drugs Svensson, T.H.
 2000
 10 S3 p. 107-109
3 p.
 artikel
306 Modulation of adenylyl cyclase activity by noradrenaline and serotonin in human platelets Palego, L.
 2000
 10 S3 p. 403-
1 p.
 artikel
307 Modulation of D2R-mediated mitogenic signalling by APDs Rogue, P.
 2000
 10 S3 p. 320-321
2 p.
 artikel
308 Modulation of neurotransmitter release via histamine H3 receptors Schlicker, E.
 2000
 10 S3 p. 199-200
2 p.
 artikel
309 Modulation of sleep EEG and nocturnal hormone secretion by neuropeptide Y in patients with depression and normal controls Steiger, A.
 2000
 10 S3 p. 276-277
2 p.
 artikel
310 Modulation of the serotonergic system and anxiety sensitivity Romano, P.
 2000
 10 S3 p. 345-
1 p.
 artikel
311 Molecular Genetics of autism: evidence for susceptibility loci Bailey, A.
 2000
 10 S3 p. 149-150
2 p.
 artikel
312 Molecular modeling of the GABAB receptor subdomains: Two putative binding sites in allosteric interaction? Bernard, P.
 2000
 10 S3 p. 212-213
2 p.
 artikel
313 Molecular pharmacology of the histamine H3 receptor Schwartz, J.-C.
 2000
 10 S3 p. 199-
1 p.
 artikel
314 Mood spectrum and residual symptoms Cassano, G.B.
 2000
 10 S3 p. 203-
1 p.
 artikel
315 Mood stabilisation with lamotrigine in rapid cycling bipolar disorder Earl, N.
 2000
 10 S3 p. 237-238
2 p.
 artikel
316 Mood stabilisation with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study Kusumakar, V.
 2000
 10 S3 p. 238-
1 p.
 artikel
317 Morning and evening plasma melatonin and dexamethasone suppression test in non-seasonal major depressive patients from Northern Greece (latitude 40–41.5°) Fountoulakis, K.N.
 2000
 10 S3 p. 267-268
2 p.
 artikel
318 MRI signal hyperintensities and chronicity of depression Heiden, A.
 2000
 10 S3 p. 279-280
2 p.
 artikel
319 Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression Januel, D.
 2000
 10 S3 p. 249-
1 p.
 artikel
320 Multiple Sclerosis (MS) resembling Landau Kleffner (LK) syndrome Kountouris, D.
 2000
 10 S3 p. 370-371
2 p.
 artikel
321 Naftidrofuryl in the treatment of vascular dementia (NaVaDe study) Möller, H.J.
 2000
 10 S3 p. 359-
1 p.
 artikel
322 Naltrexone in the treatment of craving in opiate addicts Ramah, A.
 2000
 10 S3 p. 382-
1 p.
 artikel
323 Neurobiology of anxiety disorders: Focus on neuroimaging Westenberg, H.G.M.
 2000
 10 S3 p. 189-
1 p.
 artikel
324 Neuroendocrine effects of citalopram infusion in idiopathic environmental intolerance and in chronic fatigue syndrome Itzlinger, U.
 2000
 10 S3 p. 406-
1 p.
 artikel
325 Neuroendocrine effects of ethanol in sons of alcoholics Spring, K.
 2000
 10 S3 p. 376-377
2 p.
 artikel
326 Neuroendocrine regulation in mice deficient for the corticotropin-releasing hormone receptor 1 (CRHR1): activation of the vasopressinergic system and involvement of CRHR1 in adrenocortical function Müller, M.B.
 2000
 10 S3 p. 404-405
2 p.
 artikel
327 Neuroendocrinological, biochemical and psychophysiological characteristics of chronic posttraumatic stress disorder Klumpers, U.M.H.
 2000
 10 S3 p. 339-
1 p.
 artikel
328 Neuroimaging benzodiazepine receptors: effects of disease and drugs Lingford-Hughes, A.
 2000
 10 S3 p. 168-
1 p.
 artikel
329 Neuroleptic malignant syndrome in an 72-year-old-man with Alzheimer's disease: a case report and review of the literature Gallarda, T.
 2000
 10 S3 p. 357-
1 p.
 artikel
330 Neuroleptic malignant syndrome induced by risperidone and clozapine combination Kontaxakis, V.P.
 2000
 10 S3 p. 312-
1 p.
 artikel
331 Neurological signs in schizophrenia patients: The influence of atypical versus classical antipsychotic drugs Boks, M.P.M.
 2000
 10 S3 p. 314-315
2 p.
 artikel
332 Neuronal nicotinic receptors in neurodegenerative disorders Nordberg, A.
 2000
 10 S3 p. 174-175
2 p.
 artikel
333 Neuronal nicotinic subtype selective agonists in treatment of dementia Kem, W.R.
 2000
 10 S3 p. 191-192
2 p.
 artikel
334 Neuropeptides in animal models of anxiety Landgraf, R.
 2000
 10 S3 p. 124-
1 p.
 artikel
335 Neuroprotection and regeneration in spinal cord injury Privat, A.
 2000
 10 S3 p. 154-155
2 p.
 artikel
336 Neuropsychological deficits and negative symptoms in patients with first-episode schizophrenia Schaub, A.
 2000
 10 S3 p. 326-327
2 p.
 artikel
337 Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia Wilcock, G.
 2000
 10 S3 p. 360-
1 p.
 artikel
338 Neuroradiological findings in expressive aphasia in children. Psychopathological and neuropsychological correlates Hormaechea, J.A.
 2000
 10 S3 p. 396-
1 p.
 artikel
339 Neuroreceptor imaging in depression Grasby, P.
 2000
 10 S3 p. 197-198
2 p.
 artikel
340 New anxiety disorder treatments based on novel neurobiology Gorman, J.M.
 2000
 10 S3 p. 139-140
2 p.
 artikel
341 New approaches in the treatment of brain lesions Epifanova, N.
 2000
 10 S3 p. 370-
1 p.
 artikel
342 New avenues in the treatment of dementia Winblad, B.
 2000
 10 S3 p. 191-
1 p.
 artikel
343 New data on augmentation strategies in depression Artigas, F.
 2000
 10 S3 p. 203-204
2 p.
 artikel
344 New data on serotonergic medication in migraine van den Brink, A.Maasen
 2000
 10 S3 p. 128-129
2 p.
 artikel
345 New findings suggest weak anticholinergic profile of olanzapine Tran, P.
 2000
 10 S3 p. 303-304
2 p.
 artikel
346 New potential targets in the treatment of bipolar disorder: Animal models and neuropeptides Mathé, A.A.
 2000
 10 S3 p. 144-145
2 p.
 artikel
347 Nicotine consumption in mental disorders: a clinical epidemiological perspective Wittchen, H.-U.
 2000
 10 S3 p. 119-
1 p.
 artikel
348 Nicotine dependence: Concepts from animal experiments Stolerman, I.P.
 2000
 10 S3 p. 118-
1 p.
 artikel
349 Nicotinic receptors and neurotrophic factors Belluardo, N.
 2000
 10 S3 p. 176-177
2 p.
 artikel
350 Nicotinic receptors in Alzheimer's disease Wevers, A.
 2000
 10 S3 p. 175-176
2 p.
 artikel
351 Nicotinic treatment of degenerative neuropsychiatric disorders Newhouse, P.A.
 2000
 10 S3 p. 178-179
2 p.
 artikel
352 NK-1 antagonists as antidepressants - clinical studies Kramer, M.
 2000
 10 S3 p. 122-123
2 p.
 artikel
353 NMDA receptor hypofunction and animal models of schizophrenia Jentsch, J.D.
 2000
 10 S3 p. 209-210
2 p.
 artikel
354 NMDA-sensitive glutamate antagonism: A human model for psychosis Lahti, A.C.
 2000
 10 S3 p. 211-
1 p.
 artikel
355 No association between suicidal behaviour and 5-HT2A-T102C polymorphism in alcohol dependants Preuss, U.W.
 2000
 10 S3 p. 382-
1 p.
 artikel
356 No differences in inositol monophosphatase activity and GSK-3β immunoreactivity between bipolar patients and normal controls in postmortem brain Agam, G.
 2000
 10 S3 p. 142-143
2 p.
 artikel
357 No effect of amisulpride on lithium pharmacokinetics Canal, M.
 2000
 10 S3 p. 330-331
2 p.
 artikel
358 No evidence of lateralized effects on mood after slow repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers Hermelink, D.
 2000
 10 S3 p. 274-
1 p.
 artikel
359 Nosologia and treatment of impulse disturbances Saß, H.
 2000
 10 S3 p. 207-
1 p.
 artikel
360 Novelty seeking and harm avoidance and dopamine 4 and serotonine 2A receptor gene polymorphisms Schüssler, P.
 2000
 10 S3 p. 398-
1 p.
 artikel
361 Obesity as a risk factor for antipsychotic noncompliance Weiden, P.J.
 2000
 10 S3 p. 289-290
2 p.
 artikel
362 Obsessive-compulsive symptoms in schizophrenic patients treated with clozapine Tafliński, T.
 2000
 10 S3 p. 309-
1 p.
 artikel
363 Occurrence of mirtazapine-induced delirium in organic brain disorder — Three case reports Bailer, U.
 2000
 10 S3 p. 220-
1 p.
 artikel
364 Olanzapine-associated neuroleptic malignant syndrome: Is there any overlap with the serotonin syndrome? Kontaxakis, V.P.
 2000
 10 S3 p. 313-
1 p.
 artikel
365 Olanzapine-induced neuroleptic malignant syndrome Kontaxakis, V.P.
 2000
 10 S3 p. 312-313
2 p.
 artikel
366 Olanzapine in the treatment of juvenile bipolar disorder Frazier, J.A.
 2000
 10 S3 p. 247-
1 p.
 artikel
367 Olanzapine vs. chlorpromazine — 6 weeks treatment of acute schizophrenia Dossenbach, M.
 2000
 10 S3 p. 329-
1 p.
 artikel
368 Olanzapine vs haloperidol: plasma levels and clinical efficacy on cognitive function in 37 schizophrenic patient (22 olz, 15 hal.) De Vanna, M.
 2000
 10 S3 p. 321-
1 p.
 artikel
369 Older antidepressant drugs for generalized anxiety disorder: developing the concept Rickels, K.
 2000
 10 S3 p. 171-172
2 p.
 artikel
370 Onset of action of mirtazapine on anxiety symptoms related to depression Van Hensbeek, I.
 2000
 10 S3 p. 264-265
2 p.
 artikel
371 Onset of action of mirtazapine on depression related symptoms: factor analysis of pooled data mirtazapine versus SSRIs Schutte, A.J.
 2000
 10 S3 p. 263-
1 p.
 artikel
372 Onset of response to fluoxetine treatment as assessed by the symptom questionnaire Sonawalla, S.
 2000
 10 S3 p. 278-
1 p.
 artikel
373 Opioid involvement in smoking behavior Tejwani, G.A.
 2000
 10 S3 p. 120-
1 p.
 artikel
374 Opioids and social disturbances Van Ree, J.M.
 2000
 10 S3 p. 123-124
2 p.
 artikel
375 Optimal risperidone dosage in drug-naïve first-episode schizophrenic patients Kontaxakis, V.P.
 2000
 10 S3 p. 311-
1 p.
 artikel
376 Oral Mg2+-supplementation reverses age related sleep-endocrine changes in humans Murck, H.
 2000
 10 S3 p. 373-
1 p.
 artikel
377 Orphanin FQ, an endogenous modulator of stress-induced anxiety states in animals Moreau, J.-L.
 2000
 10 S3 p. 339-340
2 p.
 artikel
378 Outcome predictors in bipolar disorder: a catamnestic study Amore, M.
 2000
 10 S3 p. 249-250
2 p.
 artikel
379 Parkinsonism and tardive dyskinesia in elderly patients Gerlach, J.
 2000
 10 S3 p. 147-148
2 p.
 artikel
380 Paroxetine is effective in the treatment of generalized anxiety disorder: results from a randomized placebo-controlled flexible dose study McCafferty, J.P.
 2000
 10 S3 p. 347-348
2 p.
 artikel
381 Partial agonist benzodiazepines: Clinical experiences Kavoussi, R.
 2000
 10 S3 p. 167-168
2 p.
 artikel
382 Patients' satisfaction with medication during psychiatric inpatient treatment Müller, M.J.
 2000
 10 S3 p. 406-407
2 p.
 artikel
383 Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain Hampel, H.
 2000
 10 S3 p. 372-373
2 p.
 artikel
384 Patterns of response to serotonergic antidepressants Benkert, O.
 2000
 10 S3 p. 161-162
2 p.
 artikel
385 PCP-site ligands and the glutamate hypothesis of schizophrenia Kornhuber, J.
 2000
 10 S3 p. 211-
1 p.
 artikel
386 Penetration of antidepressant drug into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1ab P-glycoprotein disruption Uhr, M.
 2000
 10 S3 p. 253-
1 p.
 artikel
387 Pentadecapeptide BPC 157 with anticonvulsant and anxiolytic properties interacts with GABAergic system in a complex way Jelovac, N.
 2000
 10 S3 p. 389-
1 p.
 artikel
388 Perception of chimeric faces and the brain's pattern of asymmetry in schizophrenia Kucharska-Pietura, K.
 2000
 10 S3 p. 286-
1 p.
 artikel
389 Perception of emotional prosody among schizophrenic patients Kucharska-Pietura, K.
 2000
 10 S3 p. 286-
1 p.
 artikel
390 Perception of facial affect among unilateral brain-damaged patients Kucharska-Pietura, K.
 2000
 10 S3 p. 358-
1 p.
 artikel
391 Periodic postpartum separation from the litter alters stress-reactivity and sensitivity to morphine in Long-Evans dams Kalinichev, M.
 2000
 10 S3 p. 375-376
2 p.
 artikel
392 Pharmacoepidemiology of coprescription of antidepressants and antipsychotics Rittmannsberger, H.
 2000
 10 S3 p. 111-
1 p.
 artikel
393 Pharmacokinetics of ziprasidone in children and adolescents with Tourette's syndrome Sallee, F.R.
 2000
 10 S3 p. 289-
1 p.
 artikel
394 Pharmacokinetics, tolerability, and safety of aripiprazole following single and multiple oral dose administration Mallikaarjun, S.
 2000
 10 S3 p. 306-307
2 p.
 artikel
395 Pharmacological control of aggressivity in mentally retarded adults Bertelli, M.
 2000
 10 S3 p. 386-
1 p.
 artikel
396 Pharmacological profile of newly synthesized oxotechnitium ligands for the in vivo imaging of brain 5-HT1A receptors Drossopoulou, G.
 2000
 10 S3 p. 257-258
2 p.
 artikel
397 Physical signs in psychiatry — a step towards evidence based medicine Gupta, R.K.
 2000
 10 S3 p. 223-224
2 p.
 artikel
398 PPI deficits in antipsychotic-treated, chronic schizophrenic patients Ludewig, K.
 2000
 10 S3 p. 318-
1 p.
 artikel
399 Predictive value of early antianxiety effect on the acute-antipsychotic outcome: a comparison of fluphenazine and olanzapine Martényi, F.
 2000
 10 S3 p. 305-
1 p.
 artikel
400 Predictors of death in bipolar disorder Tsai, S.-Y.M.
 2000
 10 S3 p. 227-
1 p.
 artikel
401 Predictors of hypomania occurring during the antidepressant treatment Živanović, O.
 2000
 10 S3 p. 242-243
2 p.
 artikel
402 Predictors of treatment response in Panic disorder Menini, M.
 2000
 10 S3 p. 347-
1 p.
 artikel
403 Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial Steiner, M.
 2000
 10 S3 p. 226-227
2 p.
 artikel
404 Prevalence of depressive mixed states in depressed outpatients Benazzi, F.
 2000
 10 S3 p. 219-220
2 p.
 artikel
405 Prevalence of mental disorders and their subthreshold forms in suicide attempters in Hungary Balázs, J.
 2000
 10 S3 p. 393-
1 p.
 artikel
406 Prevalence of mental disorders in a Belgian primary care setting Dierick, M.
 2000
 10 S3 p. 408-409
2 p.
 artikel
407 Processing deficits and overall cognitive impairment in Alzheimer Disease Politis, A.
 2000
 10 S3 p. 361-
1 p.
 artikel
408 Progression of corpus callosum and hippocampus atrophy as independent markers of structural disease progression in Alzheimer's disease Hampel, H.
 2000
 10 S3 p. 371-372
2 p.
 artikel
409 Prolactinsecretion of lactotropic cells is modulated by antiestrogens alone or in combination with dopaminagonists Koller, G.
 2000
 10 S3 p. 400-
1 p.
 artikel
410 Psychiatric disorders and comorbidity in high-dose and low-dose benzodiazepine users Lekka, N.P.
 2000
 10 S3 p. 334-335
2 p.
 artikel
411 Psychiatric disorders in Multiple Sclerosis Kümpfel, T.
 2000
 10 S3 p. 114-115
2 p.
 artikel
412 Psychiatric side effects during combination treatment for chronic hepatitis C with interferon-alpha and ribavirin: comparison of psychiatric patients, drug addicts and controls Schäfer, M.
 2000
 10 S3 p. 396-397
2 p.
 artikel
413 Psychological effects of MDMA (“Ecstasy”) after pretreatment with selective neuroreceptor ligands in healthy volunteers Liechti, M.E.
 2000
 10 S3 p. 374-
1 p.
 artikel
414 Psychopharmaca use in general hospital Becker, U.
 2000
 10 S3 p. 399-400
2 p.
 artikel
415 Psychosocial stress as a trigger for the adaptive modification of neuronal circuitry Hüther, G.
 2000
 10 S3 p. 162-163
2 p.
 artikel
416 Psychotropic drugs and pregnancy Bisi, A.
 2000
 10 S3 p. 390-
1 p.
 artikel
417 Psychotropic drug use in mentally retarded group home residents with behavioural problems Stolker, J.J.
 2000
 10 S3 p. 399-
1 p.
 artikel
418 QTc prolongation associated with sulpiride and haloperidol use: A pilot crossover-design study Su, K.P.
 2000
 10 S3 p. 311-312
2 p.
 artikel
419 Quantitative magnetic resonance imaging of the corpus callosum in schizophrenia Frodl, T.
 2000
 10 S3 p. 324-
1 p.
 artikel
420 Quetiapine is effective in a high-risk patient without precipitating the akathisia seen with olanzapine and risperidone Purdon, S.
 2000
 10 S3 p. 320-
1 p.
 artikel
421 Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone Kinon, B.J.
 2000
 10 S3 p. 306-
1 p.
 artikel
422 Reboxetine, a novel selective NRI, in the treatment of panic disorder Versiani, M.
 2000
 10 S3 p. 245-246
2 p.
 artikel
423 Reboxetine does not influence parasympathetic mediated autonomic neurocardiac regulation (ANR) Agelink, M.W.
 2000
 10 S3 p. 244-245
2 p.
 artikel
424 Reboxetine plus citalopram in treatment resistant depression Devarajan, S.
 2000
 10 S3 p. 280-
1 p.
 artikel
425 Reboxetine vs desipramine and imipramine: An overview of tolerability Versiani, M.
 2000
 10 S3 p. 245-
1 p.
 artikel
426 Recent advances of pharmacogenetics in psychiatry Kerwin, R.
 2000
 10 S3 p. 132-
1 p.
 artikel
427 Recent developments in the pharmaco-therapy of generalized anxiety disorder Den Boer, J.A.
 2000
 10 S3 p. 172-
1 p.
 artikel
428 Receptors and ligands Pertwee, R.G.
 2000
 10 S3 p. 181-182
2 p.
 artikel
429 Reduced central muscarinic acetylcholine receptor availability in vivo in schizophrenic patients Raedler, T.J.
 2000
 10 S3 p. 298-
1 p.
 artikel
430 Reduced phosphodiesters and high-energy phosphates in the frontal lobe of neuroleptic-free schizophrenic patients — a 31P-chemical shift spectroscopic-imaging study Smesny, S.
 2000
 10 S3 p. 397-
1 p.
 artikel
431 Reduction of increased striatal dopamine transporter density in adults with attention deficit hyperactivity disorder under methylphenidate — a study with Tc-99m-TRODAT-1-SPECT Krause, J.
 2000
 10 S3 p. 387-388
2 p.
 artikel
432 Regulation of 5-HT1A and 5-HT4 receptors in rat hippocampus by antidepressants and corticosterone Bijak, M.
 2000
 10 S3 p. 251-
1 p.
 artikel
433 Rehabilitation of refugees and forced migrants with social-stress disorders in Russia Prokudina, E.N.
 2000
 10 S3 p. 352-
1 p.
 artikel
434 Relapse prevention with olanzapine Beasley Jr., C.
 2000
 10 S3 p. 304-
1 p.
 artikel
435 Relationship between inadequate physical healthcare and poor mental health among individuals with schizophrenia Russell, J.M.
 2000
 10 S3 p. 295-296
2 p.
 artikel
436 Repetitive transcranial magnetic stimulation: Evidence for neuroprotective effects Post, A.
 2000
 10 S3 p. 373-
1 p.
 artikel
437 Repetitive transcranial magnetic stimulation in major depression — The impact of stimulation intensity on therapeutic efficacy Zwanzger, P.
 2000
 10 S3 p. 231-
1 p.
 artikel
438 Residual effects of zaleplon and zopiclone versus the effects of alcohol on actual car driving performance Vermeeren, A.
 2000
 10 S3 p. 394-
1 p.
 artikel
439 Resolution of rapid weight gain on olanzapine after substitution with quetiapine Nasr, S.J.
 2000
 10 S3 p. 319-
1 p.
 artikel
440 Results of a placebo-controlled 6-month trial with memantine in moderate to severe Alzheimer's disease (AD) Reisberg, B.
 2000
 10 S3 p. 363-364
2 p.
 artikel
441 Retrospective 1-year review of the outcomes of atypical antipsychotic use at Central Texas Veterans Health Care System Clark, W.
 2000
 10 S3 p. 300-
1 p.
 artikel
442 Riluzole intoxication in a patient with Huntington's disease — a neuropsychological case report Bodner, T.
 2000
 10 S3 p. 388-
1 p.
 artikel
443 Risperidone as an adjunctive treatment in mixed mania Vieta, E.
 2000
 10 S3 p. 239-
1 p.
 artikel
444 Risperidone augmentation in refractory obsessive compulsive disorder: An open-label study Pfanner, C.
 2000
 10 S3 p. 349-350
2 p.
 artikel
445 Risperidone effect on positive and negative symptoms of schizophrenia: A nine-month follow-up study of 375 patients Cervera-Enguix, S.
 2000
 10 S3 p. 292-
1 p.
 artikel
446 Risperidone is effective in patients with treatment-resistant schizophrenia Kocmur, M.
 2000
 10 S3 p. 284-285
2 p.
 artikel
447 Risperidone is more useful than bromperidol in the treatment of first-episode schizophrenic patients Suhiyoshi, A.
 2000
 10 S3 p. 332-
1 p.
 artikel
448 Risperidone olanzapine drug outcomes study in schizophrenia (RODOS) pooled results from German centers Albus, M.
 2000
 10 S3 p. 296-
1 p.
 artikel
449 Risperidone Olanzapine Drug Outcomes Study (RODOS): the first English results Martin, S.
 2000
 10 S3 p. 310-311
2 p.
 artikel
450 Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitation Currier, G.W.
 2000
 10 S3 p. 296-
1 p.
 artikel
451 Risperidone therapy in bipolar disorder: Results from a 6-month open-label study in Spain Vieta, E.
 2000
 10 S3 p. 240-
1 p.
 artikel
452 Risperidone treatment for acute mania: assessment of tolerability Bowden, C.
 2000
 10 S3 p. 246-
1 p.
 artikel
453 Risperidone versus pimozide for the treatment of monosymptomatic hypochondriacal psychosis Çetin, M.
 2000
 10 S3 p. 325-326
2 p.
 artikel
454 Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: Safety comparisons Conley, R.R.
 2000
 10 S3 p. 342-
1 p.
 artikel
455 Role of corticosterone and its synthesis inhibition in the discriminative stimulus effects of cocaine in rats Przegalinski, E.
 2000
 10 S3 p. 378-379
2 p.
 artikel
456 Role of 5-HT1B receptors in the activity of antidepressants in animal models Bourin, M.
 2000
 10 S3 p. 159-160
2 p.
 artikel
457 Role of serotonin and serotonin receptors in the apomorphine-induced aggressive behaviour of adult male Wistar rats Matto, V.
 2000
 10 S3 p. 386-
1 p.
 artikel
458 Safety during long-term exposure to quetiapine Gorman, A.P.
 2000
 10 S3 p. 303-
1 p.
 artikel
459 Screening for cognitive impairment in dementia — the DemTect procedure Calabrese, P.
 2000
 10 S3 p. 369-
1 p.
 artikel
460 Separation of systemic physiologic and specific cerebral drug effects in pharmacologic magnetic resonance imaging (phMRI) Kalisch, R.
 2000
 10 S3 p. 348-
1 p.
 artikel
461 Serotonin and autism Poustka, F.
 2000
 10 S3 p. 150-151
2 p.
 artikel
462 Serotonin antibodies in treatment of experimental opiate addiction: Mechanisms of action Basharova, L.
 2000
 10 S3 p. 377-
1 p.
 artikel
463 Serotonin, suicide and impulsiveness Åsberg, M.
 2000
 10 S3 p. 206-207
2 p.
 artikel
464 Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]-paroxetine binding in healthy controls and alcohol dependants and its relation to impulsivity Preuss, U.W.
 2000
 10 S3 p. 381-
1 p.
 artikel
465 Sertraline and fluoxetine treatment of OCD: a 6-month, double-blind, parallel study Bergeron, R.
 2000
 10 S3 p. 260-
1 p.
 artikel
466 Sertraline and posttraumatic stress disorder: Results of 24 weeks of open-label sertraline followed by a 28-week discontinuation study Davidson, J.
 2000
 10 S3 p. 348-349
2 p.
 artikel
467 Sertraline versus imipramine in non-melancholic depression Baca, E.
 2000
 10 S3 p. 225-
1 p.
 artikel
468 Serum cholesterol level and suicidal thoughts Kecskés, I.
 2000
 10 S3 p. 257-
1 p.
 artikel
469 Sexual dysfunctions in depressed outpatients during long-term therapy with moclobemide and SSRIs — The results of an open, prospective, observational study Fauchére, P.-A.
 2000
 10 S3 p. 263-
1 p.
 artikel
470 Sexual functional during acute and continuation therapy with fluoxetine: a prospective assessment Michelson, D.
 2000
 10 S3 p. 221-
1 p.
 artikel
471 Short term and long term effects of venlafaxine and trimipramine on cognitive psychomotor performance in patients with major depression Hemmeter, U.
 2000
 10 S3 p. 243-
1 p.
 artikel
472 Significance of the brain mineralocorticoid receptor in stress and stress-related mental disorders Gesing, A.
 2000
 10 S3 p. 271-
1 p.
 artikel
473 Simultaneous use of sertraline and hormonal replacement therapy (HRT) in women with major depression during the menopausal period Krogulski, S.
 2000
 10 S3 p. 261-262
2 p.
 artikel
474 Sleep disturbance in affective disorders: relationship to family history Papadimitriou, G.N.
 2000
 10 S3 p. 268-
1 p.
 artikel
475 Sleep EEG changes in OCD: A comparison with normal controls Matos-Pires, A.
 2000
 10 S3 p. 350-
1 p.
 artikel
476 Sleep EEG measures in major depression: Predictive markers for long-term course Hatzinger, M.
 2000
 10 S3 p. 243-244
2 p.
 artikel
477 Sleep-endocrine alterations in women with depression are markedly enhanced after menopause Antonijevic, I.A.
 2000
 10 S3 p. 277-
1 p.
 artikel
478 Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine Dossenbach, M.
 2000
 10 S3 p. 328-329
2 p.
 artikel
479 Social adjustment of patients with depression is improved with effective treatment: a venlafaxine study in general practice Lecrubier, Y.
 2000
 10 S3 p. 230-
1 p.
 artikel
480 SPECT imaging of drug effects in humans Schlaepfer, T.E.
 2000
 10 S3 p. 198-199
2 p.
 artikel
481 SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial Pallanti, S.
 2000
 10 S3 p. 127-128
2 p.
 artikel
482 Steady-state pharmacokinetics of donepezil hydrochloride in subjects with hepatic disease Reyes, J.F.
 2000
 10 S3 p. 369-370
2 p.
 artikel
483 Stress and depression: from vulnerability to treatment Newport, D.J.
 2000
 10 S3 p. 164-165
2 p.
 artikel
484 Striatal dopamin transporter in drug-naive schizophrenic patients: a 99mTc-TRODAT-1-SPECT study Schmitt, G.J.E.
 2000
 10 S3 p. 324-
1 p.
 artikel
485 Subjective evaluation of psychopharmacology and its outcome in schizophrenia Jarema, M.
 2000
 10 S3 p. 281-282
2 p.
 artikel
486 Subtype selective nicotine agonists Lloyd, K.
 2000
 10 S3 p. 177-178
2 p.
 artikel
487 Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapine Robertson Jr., J.B.
 2000
 10 S3 p. 319-320
2 p.
 artikel
488 Suicidal behavior in patients with recurrent brief depression (RBD) Pezawas, L.
 2000
 10 S3 p. 274-
1 p.
 artikel
489 Survival analyses of discontinuations as evidence of long-term effectiveness of venlafaxine ER in GAD: comparison of venlafaxine ER with placebo Montgomery, S.A.
 2000
 10 S3 p. 338-339
2 p.
 artikel
490 Switch to risperidone and olanzapine in the cohort of young schizophrenic patients Chojnacka, J.
 2000
 10 S3 p. 308-309
2 p.
 artikel
491 Symptom relief obtained with Venlafaxine versus fluoxetine in depressed patients with concomitant anxiety De Nayer, A.
 2000
 10 S3 p. 242-
1 p.
 artikel
492 Synthetic cannabinoids, potential therapeutic agents of the central nervous system Pop, E.
 2000
 10 S3 p. 184-185
2 p.
 artikel
493 Tardive dyskinesia exacerbating with mania: a case report Eşel, E.
 2000
 10 S3 p. 222-223
2 p.
 artikel
494 Targeted mutation of benzodiazepine receptors: new insights into structure and function Möhler, H.
 2000
 10 S3 p. 166-167
2 p.
 artikel
495 Test-retest reliability and concurrent validity of the SADIMoD Loonen, A.J.M.
 2000
 10 S3 p. 362-
1 p.
 artikel
496 Thalamic blood flow is reduced in OCD responders to fluvoxamine Ho Pian, K.L.
 2000
 10 S3 p. 339-
1 p.
 artikel
497 The anxiolytic effect of the novel CRH1 receptor antagonist R121919 depends on innate emotionality in rats Keck, M.E.
 2000
 10 S3 p. 272-
1 p.
 artikel
498 The anxiolytic-like effect of nafadotride, a dopamine D3 receptor antagonist, in rats Rogóż, Z.
 2000
 10 S3 p. 349-
1 p.
 artikel
499 The behavioral effects of L-tryptophan and p-chlorophenylalanine in rats with different levels of corticosteroids Fedotova, J.O.
 2000
 10 S3 p. 383-
1 p.
 artikel
500 The biochemistry and genetics of signal transduction in bipolar disorder Bondy, B.
 2000
 10 S3 p. 141-142
2 p.
 artikel
501 The burden of post-traumatic stress disorder Nutt, D.J.
 2000
 10 S3 p. 351-352
2 p.
 artikel
502 The clinical advantage of the comedication of atypical antipsychotics and antidepressants Naber, D.
 2000
 10 S3 p. 112-
1 p.
 artikel
503 The comparative analysis of NMDA blocking activity and safety of mono- and bis-cationic compounds in tests in animals Sapronov, N.S.
 2000
 10 S3 p. 384-385
2 p.
 artikel
504 The criteria for evaluating response to antipsychotics in schizophrenia Kane, J.
 2000
 10 S3 p. 129-130
2 p.
 artikel
505 The diagnosis and treatment of rapidly cycling bipolar disorder Maj, M.
 2000
 10 S3 p. 144-
1 p.
 artikel
506 The differential reinforcement of low-rate (DRL) 72 model for characterization of antidepressant agents: Noradrenaline, but not serotonin or dopamine, uptake inhibitors mimic the actions of imipramine Dekeyne, A.
 2000
 10 S3 p. 217-
1 p.
 artikel
507 The “discontinuation syndrome” in depressed patients successfully treated with sertraline Dan, I.-A.
 2000
 10 S3 p. 273-274
2 p.
 artikel
508 The effect of antidepressant drugs on transcriptional activity of dopamine D2 receptor gene promoter in the NB41A3 cells — In vitro study Góralska, M.
 2000
 10 S3 p. 255-256
2 p.
 artikel
509 The effect of atypical vs typical antipsychotic drugs on the results of neurocognitive tests in schizophrenic patients Rybakowski, J.K.
 2000
 10 S3 p. 309-
1 p.
 artikel
510 The effect of clonidine in the treatment of acute mania Tudorache, B.
 2000
 10 S3 p. 281-
1 p.
 artikel
511 The effect of fluoxetine and imipramine on c-fos expression induced by immobilization stress Kim, K.S.
 2000
 10 S3 p. 404-
1 p.
 artikel
512 The effect of quetiapine in improving cognitive impairment in schizophrenia Hellewell, J.S.E.
 2000
 10 S3 p. 300-301
2 p.
 artikel
513 The effect of risperidone on psychotic symptom and information processing in first episode schizophrenia Hyun, S.B.
 2000
 10 S3 p. 290-291
2 p.
 artikel
514 The effect of various 1,2,3,4-tetrahydroisoquinoline derivatives on 3H-dopamine and 3H-serotonin uptake in rat brain structures — In vitro studies Michaluk, J.
 2000
 10 S3 p. 364-
1 p.
 artikel
515 The effects of citalopram metabolites on dog heart in vitro : an electrophysiological study Faivre, J.F.
 2000
 10 S3 p. 250-
1 p.
 artikel
516 The effects of olanzapine on neuroendocrine responses induced by the serotonin agonist m-chlorophenylpiperazine (m-CPP) Scheepers, F.E.
 2000
 10 S3 p. 132-134
3 p.
 artikel
517 The epidemiology, natural history, and pharmacoeconomics, of social anxiety and PTSD Kessler, R.C.
 2000
 10 S3 p. 185-186
2 p.
 artikel
518 The genetics of bipolar disorders: therapeutic implications Mendlewicz, J.
 2000
 10 S3 p. 157-158
2 p.
 artikel
519 The histamine H3 receptor and its relation to normal and altered behavior Monti, J.M.
 2000
 10 S3 p. 200-201
2 p.
 artikel
520 The impact of bipolar disorders Bourgeois, M.L.
 2000
 10 S3 p. 155-156
2 p.
 artikel
521 The impact on car-driving performance of zaleplon or zolpidem administration during the night Volkerts, E.R.
 2000
 10 S3 p. 395-
1 p.
 artikel
522 The importance of the serotonergic system in fibromyalgia syndrome Schwarz, M.J.
 2000
 10 S3 p. 126-127
2 p.
 artikel
523 The incidence and duration of missed doses during SSRI treatment Meijer, W.
 2000
 10 S3 p. 254-255
2 p.
 artikel
524 The influence of antidepressive treatment on EEG in depressive patients Jernajczyk, W.
 2000
 10 S3 p. 248-
1 p.
 artikel
525 The influence of the nitric oxide synthase inhibitor L-NAME on the effects of ethanol in rats after acute ethanol administration Pokk, P.
 2000
 10 S3 p. 374-375
2 p.
 artikel
526 The MAD-B study — A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzeimer's disease Ruether, E.
 2000
 10 S3 p. 355-
1 p.
 artikel
527 The model of timid-defensive behaviour in mice: Psychotropic effects of the different treatments Verbitskaya, E.V.
 2000
 10 S3 p. 354-
1 p.
 artikel
528 The mode of action of neuropeptides and its relevance for brain diseases Hökfelt, T.
 2000
 10 S3 p. 121-122
2 p.
 artikel
529 The modulatory effects of hypericum (St. John's wort) and its chemical constituent hyperforin in passive avoidance in the rat: comparative studies with paroxetine and imipramine Misane, I.
 2000
 10 S3 p. 224-225
2 p.
 artikel
530 The Munich vulnerability study on affective disorders: HPA system changes as risk factors Modell, S.
 2000
 10 S3 p. 165-166
2 p.
 artikel
531 The new prolonged lithium compounds Zamoshchina, T.
 2000
 10 S3 p. 269-
1 p.
 artikel
532 Theobromine and tryptophan alone or in association lack potential antidepressant-like effects whereas chronic paroxetine is effective in a genetic mouse model of depressive disorder El Yacoubi, M.
 2000
 10 S3 p. 262-
1 p.
 artikel
533 The pharmacological management of psychotic behaviour in the elderly McKeith, I.G.
 2000
 10 S3 p. 146-147
2 p.
 artikel
534 The presynaptic function as target for antidepressants Popoli, M.
 2000
 10 S3 p. 160-
1 p.
 artikel
535 The prolonged changes in albino rat's anxiety depend upon primary structure of chronical administered β-casomorphins Dubynin, V.
 2000
 10 S3 p. 400-
1 p.
 artikel
536 The psychopharmacological management of the early phase of Alzheimer's disorder Müller-Spahn, F.
 2000
 10 S3 p. 148-
1 p.
 artikel
537 Therapeutic efficiency coaxil at treatment of alcoholism Bokhan, N.
 2000
 10 S3 p. 382-383
2 p.
 artikel
538 The realization of a multidisciplinary psychoactive drug selection advisor system M-PADS Van Hyfte, D.M.H.
 2000
 10 S3 p. 390-391
2 p.
 artikel
539 The relative effectiveness of selective serotonin reuptake inhibitors and tricyclic antidepressants in reducing worker absenteeism Neslusan, C.A.
 2000
 10 S3 p. 227-
1 p.
 artikel
540 The relevance of serum carbamazepine levels in affective and schizoaffective disorders Degner, D.
 2000
 10 S3 p. 222-
1 p.
 artikel
541 The role of atypical antipsychotics in managing dementia De Deyn, P.P.
 2000
 10 S3 p. 193-194
2 p.
 artikel
542 The role of the balance system in panic disorder Perna, G.
 2000
 10 S3 p. 346-
1 p.
 artikel
543 The role of the NMDA system in alcohol dependence — Dextromethorphan challenge in alcoholics and controls: Subjective response, neuroendocrinological findings, in vivo metabolic activation and clinical implications Schütz, C.G.
 2000
 10 S3 p. 379-
1 p.
 artikel
544 The selective noradrenalin reuptake inhibitor induces similar sleep EEG changes like SSRI's in patients with depression Kuenzel, H.E.
 2000
 10 S3 p. 276-
1 p.
 artikel
545 The SSRI/5-HT2A antagonist YM992 produces inverse effects compared to SSRIs on the firing activity of noradrenergic neurons Szabo, S.T.
 2000
 10 S3 p. 249-
1 p.
 artikel
546 The synergistic effect of amantadine and antidepressant drugs in the forced swimming test in rats Maj, J.
 2000
 10 S3 p. 255-
1 p.
 artikel
547 The targeted disruption of the adenosine A2A receptor in mice reduces hypokinesia caused by haloperidol or reserpine and catalepsy induced by various drugs El Yacoubi, M.
 2000
 10 S3 p. 366-367
2 p.
 artikel
548 The treatment of depression in the psychiatric practice in Switzerland: a survey study Delini-Stula, A.
 2000
 10 S3 p. 229-230
2 p.
 artikel
549 The treatment of schizophrenia in the next decades Kane, J.
 2000
 10 S3 p. 107-
1 p.
 artikel
550 The use of atypical antipsychotics in the university psychiatric hospital in Athens Kontaxakis, V.P.
 2000
 10 S3 p. 313-314
2 p.
 artikel
551 The use of citalopram in resistant OCD Marazziti, D.
 2000
 10 S3 p. 352-353
2 p.
 artikel
552 The use of knockout mice to study the role of 5-HT receptors in animal models of depression Hen, R.
 2000
 10 S3 p. 159-
1 p.
 artikel
553 The use of novel antipsychotics to improve response in schizophrenia: a naturalistic study in poor responders Altamura, A.C.
 2000
 10 S3 p. 130-131
2 p.
 artikel
554 The use of oestrogen in the prevention and treatment of Alzheimer's disease Maki, P.M.
 2000
 10 S3 p. 194-195
2 p.
 artikel
555 The use of quantitative magnetic resonance imaging and auditory evoked potentials in schizophrenic patients Meisenzahl, E.M.
 2000
 10 S3 p. 322-
1 p.
 artikel
556 The use of thyroid hormones as augmentation strategy in depression Bauer, M.
 2000
 10 S3 p. 204-205
2 p.
 artikel
557 The use of typical and atypical antipsychotics in the treatment of elderly psychotic patients Davidson, M.
 2000
 10 S3 p. 147-
1 p.
 artikel
558 The value of comedication in bipolar disorders Walden, J.
 2000
 10 S3 p. 158-159
2 p.
 artikel
559 Three randomised, placebo-controlled, double-blind trials of pregabalin treatment of Generalized Anxiety Disorder (GAD) Pande, A.C.
 2000
 10 S3 p. 344-
1 p.
 artikel
560 Thyroid function and clinical subtypes of major depression Fountoulakis, K.N.
 2000
 10 S3 p. 402-
1 p.
 artikel
561 Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study Švestka, J.
 2000
 10 S3 p. 252-253
2 p.
 artikel
562 Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multinational survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics Hellewell, J.S.E.
 2000
 10 S3 p. 301-
1 p.
 artikel
563 Tolerability and safety of donepezil in the treatment of Alzheimer's disease: results from a Post Marketing Surveillance study Sramko, C.A.
 2000
 10 S3 p. 368-
1 p.
 artikel
564 Tolerability, efficacy and cognitive effects of quetiapine in patients with Parkinson's disease treated for psychotic symptoms Juncos, J.L.
 2000
 10 S3 p. 307-
1 p.
 artikel
565 Tolerance to the anxiogenic-like effect of mCPP in the rat elevated zero-maze test after subchronic administration Lightowler, S.
 2000
 10 S3 p. 354-
1 p.
 artikel
566 Topiramate shows efficacy against mania in an open study with an on-off-on protocol Grunze, H.
 2000
 10 S3 p. 246-
1 p.
 artikel
567 Treating PTSD — SSRI's and beyond Zohar, J.
 2000
 10 S3 p. 190-
1 p.
 artikel
568 Treatment-algorithms of bipolar disorder Kasper, S.
 2000
 10 S3 p. 157-
1 p.
 artikel
569 Treatment for Alzheimer's disease — where are we going? Wilcock, G.K.
 2000
 10 S3 p. 140-141
2 p.
 artikel
570 Treatment of behavioral and psychiatric disorders in Alzheimer's disease Wahlund, L.-O.
 2000
 10 S3 p. 117-
1 p.
 artikel
571 Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil Parsa, M.A.
 2000
 10 S3 p. 302-
1 p.
 artikel
572 Treatment of nicotine dependency with bupropion Tønnesen, P.
 2000
 10 S3 p. 120-121
2 p.
 artikel
573 Treatment of psychiatric symptoms in amyotrophic lateral sclerosis (ALS) Pongratz, D.
 2000
 10 S3 p. 116-117
2 p.
 artikel
574 Treatment of psychiatric symptoms in epilepsy Krämer, G.
 2000
 10 S3 p. 115-116
2 p.
 artikel
575 Treatment of psychiatric symptoms in Parkinson's disease Höglinger, G.U.
 2000
 10 S3 p. 113-114
2 p.
 artikel
576 Treatment of somatophorm disorders in Russian' hospitals Prokudin, V.N.
 2000
 10 S3 p. 353-
1 p.
 artikel
577 Ultra-rapid detoxification of opioid addicts Scherbaum, N.
 2000
 10 S3 p. 136-
1 p.
 artikel
578 Use of Alprazolam in the treatment of apstinential syndrome with alcoholics Jakovcevska-Kujundziska, M.
 2000
 10 S3 p. 381-
1 p.
 artikel
579 Use of risperidone in psychotic and non-psychotic patients with bipolar disorder Petty, F.
 2000
 10 S3 p. 281-
1 p.
 artikel
580 Use of the number needed to treat to evaluate clinical trials of quetiapine and other atypical antipsychotics Donoghue, J.
 2000
 10 S3 p. 301-302
2 p.
 artikel
581 Use of typical and atypical antipsychotics in schizophrenia: pharmacological and clinical aspects Müller, N.
 2000
 10 S3 p. 131-132
2 p.
 artikel
582 Using cluster analysis to identify subtypes within a study population following treatment with a new pentapeptide antidepressant (statistical and clinical aspects) Feighner, J.P.
 2000
 10 S3 p. 218-219
2 p.
 artikel
583 Validation of the Delerium Rating Scale-Revised-98 (DRS-R-98) Trzepacz, P.T.
 2000
 10 S3 p. 389-390
2 p.
 artikel
584 Venlafaxine ER treatment of GAD: specific benefit of long-term treatment Meoni, P.
 2000
 10 S3 p. 337-338
2 p.
 artikel
585 Verbal memory deficits associated with unipolar affective disorder Totic, S.
 2000
 10 S3 p. 270-
1 p.
 artikel
586 24-Week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment Van Ameringen, M.A.
 2000
 10 S3 p. 336-
1 p.
 artikel
587 Weight gain associated with valproate vs. lamotrigine monotherapy in patients with epilepsy: A randomized, double-blind comparative clinical trial Biton, V.
 2000
 10 S3 p. 236-
1 p.
 artikel
588 Weight gain during treatment with mirtazapine goes along with an increase in plasma levels of cytokines and leptin Kraus, T.
 2000
 10 S3 p. 272-273
2 p.
 artikel
589 What are the optimal tests for determining enhanced cognitive function in humans? Wesnes, K.A.
 2000
 10 S3 p. 201-202
2 p.
 artikel
590 What general practitioners recommend to psychiatric patients Seemann, U.
 2000
 10 S3 p. 408-
1 p.
 artikel
591 1-Year follow-up of pharmacological and psychoeducational treatment for 164 eating disordered subjects Ruggiero, G.M.
 2000
 10 S3 p. 396-
1 p.
 artikel
592 Ziprasidone's effect on anxiety in a group of outpatients with stable schizophrenia Schooler, N.R.
 2000
 10 S3 p. 288-
1 p.
 artikel
                             592 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland